AstraZeneca Pharma India gets CDSCO nod to import pharmaceutical formulations of Eculizumab Ruchika Sharma17 Jan 2025 1:32 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for...
AstraZeneca Voydeya approved in EU as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia Ruchika Sharma26 April 2024 4:10 PM ISTAstraZeneca has announced that Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or...
USFDA nod to Voydeya as add on therapy to ravulizumab or eculizumab for extravascular haemolysis in adults with rare disease PNH: AstraZeneca Ruchika Sharma1 April 2024 3:18 PM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the...
AstraZeneca blood disorder drug recommended for EU nod Ruchika Sharma27 Feb 2024 11:29 AM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) as an...
AstraZeneca Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder Ruchika Sharma22 Oct 2023 4:00 PM ISTCambridge: AstraZeneca has announced that Soliris (eculizumab) has been approved in China for the treatment of adult patients with neuromyelitis...
AstraZeneca Soliris approved in Japan for paediatric patients with generalised myasthenia gravis Ruchika Sharma29 Aug 2023 4:14 PM ISTCambridge: AstraZeneca's Soliris (eculizumab) has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis...
AstraZeneca Soliris approved in EU for children, adolescents with refractory generalised myasthenia gravis Ruchika Sharma28 July 2023 2:30 PM ISTSoliris (eculizumab) is a first-in-class C5 complement inhibitor.
AstraZeneca Soliris recommended for nod in EU by CHMP for children, adolescents with refractory generalised myasthenia gravis Ruchika Sharma26 Jun 2023 4:37 PM ISTSoliris is a first-in-class C5 complement inhibitor.
AstraZeneca Soliris approved in China for adults with refractory generalised myasthenia gravis Ruchika Sharma14 Jun 2023 10:00 AM ISTCambridge: AstraZeneca has announced that Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory...
AstraZeneca to acquire Alexion in USD 39 billion deal to expand immunology Ruchika Sharma14 Dec 2020 1:15 PM ISTFrankfurt: Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away...
